309 related articles for article (PubMed ID: 24846518)
1. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.
Thaçi D; Unnebrink K; Sundaram M; Sood S; Yamaguchi Y
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):353-360. PubMed ID: 24846518
[TBL] [Abstract][Full Text] [Related]
2. Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
Tillett W; Egeberg A; Sonkoly E; Gorecki P; Tjärnlund A; Buyze J; Wegner S; McGonagle D
Arthritis Res Ther; 2023 Sep; 25(1):169. PubMed ID: 37715294
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis.
Orbai AM; Chakravarty SD; You Y; Shawi M; Yang YW; Merola JF
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2859-2868. PubMed ID: 37713133
[TBL] [Abstract][Full Text] [Related]
4. Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
Egeberg A; Hawkes JE; Somani N; Burge R; See K; Gallo G; McKean-Matthews M; Gooderham M; Han G; Armstrong A
Dermatol Ther (Heidelb); 2024 Apr; 14(4):1007-1018. PubMed ID: 38647975
[TBL] [Abstract][Full Text] [Related]
5. Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis.
Armstrong AW; Park SH; Patel V; Hogan M; Wang WJ; Davidson D; Chirikov V
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2589-2603. PubMed ID: 37525000
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.
Elewski BE; Baker CS; Crowley JJ; Poulin Y; Okun MM; Calimlim B; Geng Z; Reyes Servin O; Rich PA
J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):2168-2178. PubMed ID: 31304993
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations.
Jo SJ; Huang YH; Tsai TF; Kim BS; Reich K; Saadoun C; Chang CL; Yang YW; Youn SW
J Dermatol; 2023 Sep; 50(9):1180-1189. PubMed ID: 37341137
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
Strober B; Bachelez H; Crowley J; Elewski BE; Gooderham M; Menter A; Strohal R; Chen MM; Wu T; Zhan T; Photowala H; Armstrong A
J Eur Acad Dermatol Venereol; 2024 May; 38(5):864-872. PubMed ID: 38179809
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study.
Li Y; Lv C; Dang L; Lin B; Tao J; Zhang C; Zhou X; Ma H; Lu Y; Chen R; Li J; Dou G; Liang Y; Liang Y; Shi Y
Dermatol Ther (Heidelb); 2024 Apr; 14(4):907-918. PubMed ID: 38536616
[TBL] [Abstract][Full Text] [Related]
10. Nail involvement in adult patients with plaque-type psoriasis: prevalence and clinical features.
Schons KR; Beber AA; Beck Mde O; Monticielo OA
An Bras Dermatol; 2015; 90(3):314-9. PubMed ID: 26131859
[TBL] [Abstract][Full Text] [Related]
11. Outcome following a short period of adalimumab dose escalation as rescue therapy in psoriatic patients.
Bardazzi F; Bigi L; Campanati A; Conti A; Di Lernia V; Di Nuzzo S; Kaleci S; Lasagni C; Offidani AM; Giacchetti A; Nicolini M; Bettacchi A; Rosa L; Sacchelli L
Eur J Dermatol; 2020 Apr; ():. PubMed ID: 32266875
[TBL] [Abstract][Full Text] [Related]
12. Rapid response of nail psoriasis to secukinumab in patients with moderate to severe psoriasis after 12 weeks of treatment with a total of 24 weeks of follow-up.
Go GM; Hong YJ; Lee HJ; Kim M
Australas J Dermatol; 2024 May; 65(3):e13-e20. PubMed ID: 38288519
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study.
Gebauer K; Spelman L; Yamauchi PS; Bagel J; Nishandar T; Crane M; Kopeloff I; Kothekar M; Yao SL; Sofen HL
J Am Acad Dermatol; 2024 Jul; 91(1):91-99. PubMed ID: 38554938
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of ixekizumab for the treatment of moderate-to-severe plaque psoriasis with involvement of difficult-to-treat areas: A 52-week multicenter retrospective study.
Valenti M; Gargiulo L; Ibba L; Cortese A; Toso F; Orsini D; Lora V; Frascione P; Sena P; Carugno A; Assorgi C; Costanzo A; Narcisi A
J Dermatol; 2024 Jun; 51(6):839-843. PubMed ID: 38292002
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Feldman SR; Merola JF; Pariser DM; Zhang J; Zhao Y; Mendelsohn AM; Gottlieb AB
J Dermatolog Treat; 2022 May; 33(3):1670-1675. PubMed ID: 33678106
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G-EPOSS study.
Gerdes S; Ostendorf R; Süß A; Schadeck T; Taut F; Makuc J; Scharfenberger L; Jacobsen S; Trenkler N; Behrens J; Joks G; Tabori S; Mortazawi D
J Eur Acad Dermatol Venereol; 2024 Apr; ():. PubMed ID: 38602225
[TBL] [Abstract][Full Text] [Related]
17. Palmoplantar pustulosis with fulminant dystrophic 20-nail psoriasis in a patient receiving adalimumab therapy.
Mishra V; Daniel RC; Elmets CA; Levin A; Elewski BE
J Drugs Dermatol; 2013 Jan; 12(1):16-7. PubMed ID: 23377322
[No Abstract] [Full Text] [Related]
18. Induction of psoriatic scalp and nail lesions in a patient treated with Ofatumumab: A potential autoimmune dysregulation induced by anti-CD 20 therapy.
Herzum A; Orsi SM; Ciccarese G; Occella C; Viglizzo G
Skin Res Technol; 2024 Mar; 30(3):e13662. PubMed ID: 38509841
[No Abstract] [Full Text] [Related]
19. Comparative Study of Clinical and Dermoscopic Features in Nail Psoriasis.
Wanniang N; Navya A; Pai V; Ghodge R
Indian Dermatol Online J; 2020; 11(1):35-40. PubMed ID: 32055506
[TBL] [Abstract][Full Text] [Related]
20. Guselkumab in Patients with Scalp Psoriasis: A post hoc Analysis of the VOYAGE 2 Phase III Randomized Clinical Trial.
Sonkoly E; Maul JT; Megna M; Gorecki P; Crombag E; Buyze J; Savage L
Acta Derm Venereol; 2024 Mar; 104():adv18672. PubMed ID: 38436429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
